sr 14150 profile

SR 14150: mixed NOP and mu-opioid receptor ligand and antinociceptive; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9905428
CHEMBL ID	101454
SCHEMBL ID	15794608
MeSH ID	M0521523

Synonym
bdbm50147740
1-(1-cyclooctyl-piperidin-4-yl)-1,3-dihydro-indol-2-one
CHEMBL101454 ,
709024-69-1
2h-indol-2-one, 1-(1-cyclooctyl-4-piperidinyl)-1,3-dihydro-
SCHEMBL15794608
1-(1-cyclooctylpiperidin-4-yl)-3h-indol-2-one
DTXSID60432666
sr-14150
sr14150
1-(1-cyclooctylpiperidin-4-yl)-indolin-2-one
unii-1o88c1nas7
sr 14150
1o88c1nas7 ,
AKOS040746374

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Mu-type opioid receptor	Homo sapiens (human)	Ki	0.0299	0.0000	0.4197	10.0000	AID150850; AID1628144; AID749840
Kappa-type opioid receptor	Homo sapiens (human)	Ki	0.0427	0.0000	0.3624	10.0000	AID147995; AID749839
Nociceptin receptor	Homo sapiens (human)	Ki	0.0014	0.0000	0.0337	0.5000	AID1282209; AID147410; AID1628143; AID749841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Mu-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.0990	0.0000	0.3263	9.4000	AID749836
Kappa-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.2760	0.0000	0.2244	8.9900	AID749834
Nociceptin receptor	Homo sapiens (human)	EC50 (µMol)	0.0206	0.0001	0.0089	0.0630	AID147409; AID1628145; AID749838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)
eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
response to estrogen	Kappa-type opioid receptor	Homo sapiens (human)
estrous cycle	Kappa-type opioid receptor	Homo sapiens (human)
response to ethanol	Kappa-type opioid receptor	Homo sapiens (human)
regulation of saliva secretion	Kappa-type opioid receptor	Homo sapiens (human)
behavioral response to cocaine	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of temperature stimulus	Kappa-type opioid receptor	Homo sapiens (human)
defense response to virus	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to glucose stimulus	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of p38MAPK cascade	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Kappa-type opioid receptor	Homo sapiens (human)
response to acrylamide	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
conditioned place preference	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
calcium-mediated signaling	Nociceptin receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Nociceptin receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Nociceptin receptor	Homo sapiens (human)
sensory perception	Nociceptin receptor	Homo sapiens (human)
sensory perception of pain	Nociceptin receptor	Homo sapiens (human)
response to estradiol	Nociceptin receptor	Homo sapiens (human)
positive regulation of urine volume	Nociceptin receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Nociceptin receptor	Homo sapiens (human)
eating behavior	Nociceptin receptor	Homo sapiens (human)
negative regulation of cAMP-mediated signaling	Nociceptin receptor	Homo sapiens (human)
estrous cycle	Nociceptin receptor	Homo sapiens (human)
negative regulation of blood pressure	Nociceptin receptor	Homo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	Nociceptin receptor	Homo sapiens (human)
regulation of locomotor rhythm	Nociceptin receptor	Homo sapiens (human)
conditioned place preference	Nociceptin receptor	Homo sapiens (human)
neuropeptide signaling pathway	Nociceptin receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
nociceptin receptor activity	Nociceptin receptor	Homo sapiens (human)
G protein-coupled receptor activity	Nociceptin receptor	Homo sapiens (human)
protein binding	Nociceptin receptor	Homo sapiens (human)
neuropeptide binding	Nociceptin receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Nociceptin receptor	Homo sapiens (human)
cytoplasmic vesicle	Nociceptin receptor	Homo sapiens (human)
plasma membrane	Nociceptin receptor	Homo sapiens (human)
neuron projection	Nociceptin receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID150850	Binding affinity against human Opioid receptor mu 1 on CHO cell membranes was determined by [3H]DAMGO displacement.	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID1628144	Displacement of [3H]DAMGO from recombinant human mu opioid receptor expressed in CHO cell membranes	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
AID749839	Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID749841	Displacement of [3H] N/OFQ from human nociceptin receptor transfected in CHO cells	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID749838	Agonist activity at human nociceptin receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID147995	Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID147410	Binding affinity against human Nociceptin receptor on CHO cell membranes by [3H]N/OFQ displacement.	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID749835	Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis relative to control	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID147412	Percent stimulation of [35S]GTP-gamma-S, binding to human Nociceptin receptor in cell membranes	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID749840	Displacement of [3H]DAMGO from human mu opioid receptor transfected in CHO cells	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID147409	Concentration required for stimulation of [35S]GTP-gamma-S, binding to human Nociceptin receptor in cell membranes	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID148370	Inhibition of [3H]Cl-DPDPE binding to human opioid receptor delta 1 expressed in CHO cells; Not determined	2004	Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12	A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
AID1628145	Agonist activity at human nociceptin opioid receptor expressed in CHO cell membranes after 60 mins by GTPgamma(35)S binding assay	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
AID1628143	Displacement of [3H]nociceptin/orphanin FQ from recombinant human nociceptin opioid receptor expressed in CHO cell membranes	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
AID749833	Agonist activity at human kappa opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis relative to control	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID749834	Agonist activity at human kappa opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID749837	Agonist activity at human nociceptin receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis relative to control	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID749836	Agonist activity at human mu opioid receptor transfected in CHO cells assessed as stimulation of [35S]GTPgammaS binding by liquid scintillation counting analysis	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
AID1282209	Displacement of [3H]N/OFQ from human nociceptin receptor	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (33.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (66.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	3.23	1	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	3.23	1
olmesartan olmesartan: an active metabolite of CS 866	3.23	1	biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent
buprenorphine Buprenorphine: A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.. buprenorphine : A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.	2.04	1	morphinane alkaloid	delta-opioid receptor antagonist; kappa-opioid receptor antagonist; mu-opioid receptor agonist; opioid analgesic
n(6)-cyclopentyladenosine [no description available]	3.23	1
4-(1h-imidazol-4-ylmethyl)piperidine 4-(1H-imidazol-4-ylmethyl)piperidine: structure in first source	3.23	1	piperidines
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	3.23	1
nalorphine Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.	3.23	1	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	2.06	1	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.59	2	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
fr 190997 FR 190997: structure given in first source	3.23	1
ro 64-6198 Ro 64-6198: an orphanin FQ/nociceptin receptor agonist; structure in first source	2.08	1
sb-612111 [no description available]	3.23	1
4-[3-(1H-imidazol-5-yl)propyl]piperidine [no description available]	3.23	1	aralkylamine
cebranopadol [no description available]	3.23	1
piperidines Piperidines: A family of hexahydropyridines.	2.06	1
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	2.04	1	nucleoside triphosphate analogue

Condition	Relationship Strength	Studies
Pain, Chronic [description not available]	2.06	1
Allodynia [description not available]	2.06	1
Chronic Pain Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.	2.06	1
Acute Pain Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.	2.06	1
Ache [description not available]	2.04	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.04	1

sr 14150

Description

Cross-References

Synonyms (15)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Biological Processes (48)

Molecular Functions (12)

Ceullar Components (20)

Bioassays (19)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.79

Study Types

sr 14150

Description

Cross-References

Synonyms (15)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Biological Processes (48)

Molecular Functions (12)

Ceullar Components (20)

Bioassays (19)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.79

Study Types

Related Drugs (17)

Related Conditions (6)